查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678178

2025年全球寡核苷酸治療市場報告

Oligonucleotide Therapy Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

寡核苷酸治療市場規模預計在未來幾年將快速成長。到 2029 年，這一數字將成長至 98.2 億美元，複合年成長率為 12.3%。預測期內的成長可歸因於研發投資、全球市場滲透、治療領域擴張、緩解疾病策略和監管適應。預測期內的關鍵趨勢包括客製化療法、遞送系統的進步、 RNA干擾(RNAI) 的進步、反義寡核苷酸的創新以及基因編輯技術的整合。

預計預測期內全球癌症患者數量的增加將促進寡核苷酸治療市場的成長。例如，截至2022年1月，美國癌症協會預測美國將有約190萬例新診斷癌症病例，609,360例癌症相關死亡病例，平均每天約有1,670人死亡。全球最常見的癌症是肺癌、攝護腺癌、腸癌和女性乳癌，佔所有新癌症病例的 43%。因此，全球癌症發生率的快速成長將在未來幾年推動寡核苷酸治療市場的需求。

政府針對醫療保健研究和開發的舉措預計將推動寡核苷酸治療市場的成長。這些措施包括不同層級（地方、地區、國家和國際）政府當局為解決具體問題、實現既定目標和為社會帶來積極計劃而實施的具體行動、計劃、政策和項目。各政府機構已啟動醫療保健計劃，以支持包括寡核苷酸療法在內的各個方面。 2022年，英國政府承諾向衛生和社會保障部提供2.6億英鎊（2.7065億美國）的資金，以促進醫療保健研究和製造。該資金由英國商業、工業和戰略部和衛生與公眾服務部提供，旨在透過新的隱私保護平台和臨床研究服務來支持 NHS主導的診斷​​和治療健康研究。此外，也撥款6,000萬英鎊（6,360萬美國）支持英國生命科學製造業的擴張。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場 - 宏觀經濟情境 宏觀經濟情境包括利率、通膨、地緣政治、新冠疫情和市場復甦的影響

第5章 全球成長分析與策略分析框架

  • 全球寡核苷酸治療學PESTEL分析（政治、社會、科技、環境、法律、促進因素、限制因素）
  • 最終用途產業分析
  • 全球寡核苷酸治療市場：成長率分析
  • 全球寡核苷酸治療市場表現：規模與成長，2019-2024
  • 全球寡核苷酸治療市場預測：規模與成長，2024-2029 年，2034 年
  • 全球寡核苷酸治療總目標市場（TAM）

第6章市場區隔

  • 全球寡核苷酸治療市場類型、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 反義寡核苷酸
  • 適體
  • 其他類型
  • 全球寡核苷酸治療市場的應用、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 感染疾病
  • 腫瘤學
  • 神經退化性疾病
  • 心血管疾病
  • 腎臟疾病
  • 其他最終用戶
  • 全球寡核苷酸治療市場（依最終使用者、績效及預測），2019-2024 年、2024-2029 年及 2034 年
  • 醫院
  • 研究機構
  • 全球寡核苷酸治療市場反義寡核苷酸細分市場，依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • RNA標靶反義寡核苷酸
  • DNA標靶反義寡核苷酸
  • 化學修飾的反義寡核苷酸
  • 全球寡核苷酸治療市場、適體細分、類型、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • DNA適體
  • RNA適體
  • 小分子適體
  • 全球寡核苷酸治療市場及其他細分市場，依類型、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • siRNA（小干擾RNA）
  • miRNA（微型RNA）
  • 脫氧核糖核酸酶和核酶
  • 用於基因編輯的合成寡核苷酸

第7章 區域和國家分析

  • 全球寡核苷酸治療市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球寡核苷酸治療市場：依國家/地區、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 寡核苷酸治療市場：競爭格局
  • 寡核苷酸治療市場：公司簡介
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
    • BioNTech SE Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • Moderna Inc.
  • Biogen Inc.
  • Jazz Pharmaceuticals plc
  • QIAGEN Company
  • Alnylam Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Ionis Pharmaceuticals Inc.
  • Akcea Therapeutics Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Dicerna Pharmaceuticals Inc.
  • SomaGenics Inc.
  • Wave Life Sciences Ltd.
  • Exicure Inc.
  • Avidity Biosciences Inc.
  • Miragen Therapeutics Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年寡核苷酸治療市場：提供新機會的國家
  • 寡核苷酸治療市場2029：細分領域帶來新機會
  • 寡核苷酸治療市場2029：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r26811

Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).

The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $5.55 billion in 2024 to $6.18 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $9.82 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.

The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally-lung, prostate, bowel, and female breast cancer-constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.

Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was allocated to assist in expanding life sciences manufacturing in the UK.

Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.

Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.

Major companies operating in the oligonucleotide therapy market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gilead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
  • 2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
  • 3) By End User: Hospitals; Research Institutes
  • Subsegments:
  • 1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides; DNA-Targeted Antisense Oligonucleotides; Chemically Modified Antisense Oligonucleotides
  • 2) By Aptamer: DNA Aptamers; RNA Aptamers; Small Molecule Aptamers
  • 3) By Other Types: siRNA (Small Interfering RNA); miRNA (Micro RNA); DNAzyme And Ribozymes; Synthetic Oligonucleotides For Gene Editing
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Gilead Sciences Inc.; BioNTech SE
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oligonucleotide Therapy Market Characteristics

3. Oligonucleotide Therapy Market Trends And Strategies

4. Oligonucleotide Therapy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Oligonucleotide Therapy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Oligonucleotide Therapy Market Growth Rate Analysis
  • 5.4. Global Oligonucleotide Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Oligonucleotide Therapy Total Addressable Market (TAM)

6. Oligonucleotide Therapy Market Segmentation

  • 6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antisense Oligonucleotide
  • Aptamer
  • Other Types
  • 6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Infectious Diseases
  • Oncology
  • Neurodegenerative Disorders
  • Cardiovascular Diseases
  • Kidney Diseases
  • Other End-User
  • 6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Research Institutes
  • 6.4. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • RNA-Targeted Antisense Oligonucleotides
  • DNA-Targeted Antisense Oligonucleotides
  • Chemically Modified Antisense Oligonucleotides
  • 6.5. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Aptamer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA Aptamers
  • RNA Aptamers
  • Small Molecule Aptamers
  • 6.6. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • siRNA (Small Interfering RNA)
  • miRNA (Micro RNA)
  • DNAzyme And Ribozymes
  • Synthetic Oligonucleotides For Gene Editing

7. Oligonucleotide Therapy Market Regional And Country Analysis

  • 7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oligonucleotide Therapy Market

  • 8.1. Asia-Pacific Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oligonucleotide Therapy Market

  • 9.1. China Oligonucleotide Therapy Market Overview
  • 9.2. China Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oligonucleotide Therapy Market

  • 10.1. India Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oligonucleotide Therapy Market

  • 11.1. Japan Oligonucleotide Therapy Market Overview
  • 11.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oligonucleotide Therapy Market

  • 12.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oligonucleotide Therapy Market

  • 13.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oligonucleotide Therapy Market

  • 14.1. South Korea Oligonucleotide Therapy Market Overview
  • 14.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oligonucleotide Therapy Market

  • 15.1. Western Europe Oligonucleotide Therapy Market Overview
  • 15.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oligonucleotide Therapy Market

  • 16.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oligonucleotide Therapy Market

  • 17.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oligonucleotide Therapy Market

  • 18.1. France Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oligonucleotide Therapy Market

  • 19.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oligonucleotide Therapy Market

  • 20.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oligonucleotide Therapy Market

  • 21.1. Eastern Europe Oligonucleotide Therapy Market Overview
  • 21.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oligonucleotide Therapy Market

  • 22.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oligonucleotide Therapy Market

  • 23.1. North America Oligonucleotide Therapy Market Overview
  • 23.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oligonucleotide Therapy Market

  • 24.1. USA Oligonucleotide Therapy Market Overview
  • 24.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oligonucleotide Therapy Market

  • 25.1. Canada Oligonucleotide Therapy Market Overview
  • 25.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oligonucleotide Therapy Market

  • 26.1. South America Oligonucleotide Therapy Market Overview
  • 26.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oligonucleotide Therapy Market

  • 27.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oligonucleotide Therapy Market

  • 28.1. Middle East Oligonucleotide Therapy Market Overview
  • 28.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oligonucleotide Therapy Market

  • 29.1. Africa Oligonucleotide Therapy Market Overview
  • 29.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Oligonucleotide Therapy Market Competitive Landscape
  • 30.2. Oligonucleotide Therapy Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis

31. Oligonucleotide Therapy Market Other Major And Innovative Companies

  • 31.1. Moderna Inc.
  • 31.2. Biogen Inc.
  • 31.3. Jazz Pharmaceuticals plc
  • 31.4. QIAGEN Company
  • 31.5. Alnylam Pharmaceuticals Inc.
  • 31.6. Sarepta Therapeutics Inc.
  • 31.7. Ionis Pharmaceuticals Inc.
  • 31.8. Akcea Therapeutics Inc.
  • 31.9. Arrowhead Pharmaceuticals Inc.
  • 31.10. Dicerna Pharmaceuticals Inc.
  • 31.11. SomaGenics Inc.
  • 31.12. Wave Life Sciences Ltd.
  • 31.13. Exicure Inc.
  • 31.14. Avidity Biosciences Inc.
  • 31.15. Miragen Therapeutics Inc.

32. Global Oligonucleotide Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

34. Recent Developments In The Oligonucleotide Therapy Market

35. Oligonucleotide Therapy Market High Potential Countries, Segments and Strategies

  • 35.1 Oligonucleotide Therapy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Oligonucleotide Therapy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Oligonucleotide Therapy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer